Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans
Humboldt-Universität zu Berlin · University of California, Davis · +9 more institutions
Abstract
The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines raises concern about a loss of lean body mass (LBM) and skeletal muscle. In this work, we present four pre-clinical studies and a proof-of-concept clinical trial that address this issue. We report that in obese mice, GLP-1 medicines predominantly reduce body fat alongside a small but significant decrease in LBM. Among lean tissues, loss of liver mass exceeds change in muscle mass. While absolute muscle mass and strength decrease, relative muscle mass and strength improve, resulting in better running performance. Interestingly, while atrophy is similar during immobilization, GLP-1 medicines have a distinct effect on the muscle…
Citation impact
- FWCI
- 73.37
- Percentile
- 100%
- References
- 53
Authors
22Topics & keywords
- Weight loss
- Function (biology)
- Muscle mass
- Obesity
- Loss function
- Skeletal muscle
- Zero hunger
Funding
- UOUniversity of Pennsylvania
- ECEuropean CommissionAwards: 101044445, SFB1123
- DFDeutsche ForschungsgemeinschaftAwards: SFB1123, TRR152, GRK 2816/1, DFG TRR296, TRR296
- MFMinisterium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen
- NINational Institutes of Health
- UOUniversity of California, Davis
- LLeibniz-Gemeinschaft
- NINational Institute of Diabetes and Digestive and Kidney Diseases